ProTeXt

Regenative Labs Introduces AmnioText™ Dual-Layer Patch

Retrieved on: 
Thursday, September 16, 2021
Health, Medicare, ProTeXt, CEO, FDA, Technology, HCPCS, CFR, CMS, Tissue, Patient, Centers for Medicare & Medicaid Services, Physician, Labs, Center, Redbook, Hospital, Research, Pharmaceutical industry

PENSACOLA, Fla., Sept. 16, 2021 /PRNewswire-PRWeb/ -- Regenative Labs, the established leader in the connective tissue allograft space, today launched AmnioText Dual-Layer Patch for wounds.

Key Points: 
  • PENSACOLA, Fla., Sept. 16, 2021 /PRNewswire-PRWeb/ -- Regenative Labs, the established leader in the connective tissue allograft space, today launched AmnioText Dual-Layer Patch for wounds.
  • The Regenative Labs current suite of products are regulated by the FDA under 21 CFR part 1271 section 361, are minimally manipulated and for homologous use only.
  • "As we continue our pioneering innovation at Regenative Labs, we're proud to open yet another new market to serve patients with the introduction of AmnioText, a wound covering technology," said Tyler C. Barrett, CEO of Regenative Labs.
  • Regenative Labs has a laser-focused, expert product research and development team which follows FDA guidelines for minimal manipulation and homologous use.